Novo Nordisk’s CEO Mike Doustdar spent all day Monday telling investors exactly what the company is not: a one-trick pony. At the company’s capital markets day in London, he made a plain promise: Novo will launch at least five multi-blockbuster drugs by 2030 and match other major pharma firms on revenue growth. The catch is that the company will have to start selling some of its medicines more like consumer goods than traditional prescriptions.
Doustdar presented a strategy that pushes Novo into disease areas outside diabetes and obesity, and he said the company “will be more active within business development,” an acknowledgment that investors have long worried Novo is too reliant on its landmark GLP-1 drugs. The move is a direct answer to those concerns.
Novo shares dropped 5% during Doustdar’s opening remarks, a sign that investors wanted more specifics.
Doustdar’s opening promise
The CEO’s pitch was simple on the surface. Five multi-blockbusters by 2030, revenue growth on par with other major pharma firms, and a new push into disease areas outside the company’s traditional strongholds.
The company is betting that its success with obesity treatments can be copied elsewhere. Novo’s GLP-1 drugs have taken off in weight loss, and the strategy now is to treat other conditions the same way, as if they were consumer products rather than prescription medicines.
Doustdar did not name the five drugs by name, and he did not say which disease areas would get the new investment. He did say the company “will be more active within business development,” which is a direct response to investor concerns about Novo’s reliance on GLP-1.
What the business development promise means
When a pharma company says it will be more active in business development, it is a coded way of saying it is open to deals. That could mean partnerships, licensing agreements, or outright purchases of smaller companies or their pipelines.
Doustdar’s comment suggests he knows that reliance cannot continue indefinitely.
Whether investors will accept that promise is another matter. A 5% drop in the share price during his opening remarks suggests they are not yet convinced.
The strategy Doustdar outlined
Doustdar’s full presentation covered the company’s current pipeline and its plans for the future. The core of the strategy is expansion beyond diabetes and obesity. That means Novo will be looking at new disease areas for products to add to its portfolio.
The company also wants to sell some of its medicines more like consumer goods. That is a significant shift for a firm that has spent decades selling prescription drugs through doctors and pharmacies. The idea is that certain products can be marketed and sold more like everyday consumer items, which would be a major change in how Novo operates.
What investors wanted to hear
Investors were not reassured by the opening remarks. The 5% drop in shares during Doustdar’s speech suggests they wanted more specifics.
The drop in shares was a direct sign of investor disappointment. Doustdar’s remarks were broad and aspirational, but they did not give specific details on the five multi-blockbusters, the disease areas they would target, or how the company would achieve the 2030 goals.
The company has been dealing with investor pressure for years over its reliance on GLP-1. The business development promise is a direct attempt to answer that pressure.
The road to 2030
Doustdar’s plan is ambitious. Five multi-blockbusters by 2030 is a big target, and matching other major pharma firms on revenue growth is not an easy benchmark to meet.
The strategy is a clear attempt to diversify Novo’s risk. The company has been successful with GLP-1, but it knows that success cannot last forever. By moving into new disease areas and changing how it sells its products, Novo is trying to create a more stable foundation for future growth.
Whether the plan works depends on execution. Doustdar has laid out the direction, but the details will matter more than the promise.
The numbers at a glance
| Date | Event | Result |
|---|---|---|
| Monday | Capital markets day | Doustdar outlines strategy |
| Monday | Opening remarks | Shares drop 5% |
| 2030 | Target | Five multi-blockbusters |
| 2030 | Target | Revenue growth on par with other major pharma firms |
The problem is that the company has been under pressure for years over its reliance on GLP-1, and the business development promise is a direct attempt to answer that pressure. The 5% drop in shares during his opening remarks shows that the promise alone is not enough.
The 2030 target is a long way off, and a lot can happen between now and then. Novo has the pedigree to deliver on its ambitions, but the track record on diversification has been mixed.
Doustdar’s presentation was a step in the right direction, but the proof will come in the details. The company has promised before, and the market is waiting to see if this time is different.
See the a run of 34 images at STAT.
Get the Notebook.
The day's best stories and every fresh verdict, in plain English, in your inbox by seven. One email a day, no more.